Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

July 14, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 14, 2014-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Terrence C. Kearney to its Board of Directors and to the position of Chair of the Audit Committee.

"Terry brings significant industry experience, corporate leadership and financial expertise to Acceleron and we feel he will be a valuable contributor to our board," said John Knopf, Ph.D., Chief Executive Officer of Acceleron. "In particular, Terry's financial and managerial experience makes him well-suited to serve as the Chair our Audit Committee."

Terrence C. Kearney has more than three decades of global healthcare experience at major pharmaceutical and life sciences companies. Most recently, Mr. Kearney served on the executive management team for Hospira, Inc. where he held the role of Chief Operating Officer from 2006 through 2011 and Chief Financial Officer from 2004 to 2006. In these roles, Mr. Kearney had broad responsibility for the company's global operations, including commercial, manufacturing and research and development activities, and financial management strategies. Prior to Hospira, Mr. Kearney spent 25 years at Abbott Laboratories in various financial management roles, including Vice President and Treasurer. Mr. Kearney earned a Bachelor's degree in Biology from the University of Illinois and a Master's in Business Administration from the University of Denver. Mr. Kearney serves as Chair of the Audit Committee and member of the Management Development and Compensation Committee for Vertex Pharmaceuticals.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.